TB-500: the recovery peptide.

TB-500 is a synthetic version of a peptide your body already makes — a fragment of a larger protein called thymosin beta-4. In research circles, it is one of the most-discussed compounds for recovery, tissue repair, and flexibility.

Where it comes from

Thymosin beta-4 is a naturally-occurring protein found in nearly every tissue in your body. It plays a role in cell migration, blood vessel formation, and wound healing — it is one of the proteins your body uses to coordinate the repair process after injury.

TB-500 is a synthetic peptide based on a specific active fragment of that larger thymosin beta-4 molecule. Rather than synthesizing the entire protein (which is large and complex), researchers identified the shorter sequence that appears to carry much of the regenerative activity, and synthesized that fragment for study.

What research has explored

Most TB-500 research has been preclinical — animal models and cell studies, with some specific veterinary applications (it has been used in horse racing, which is part of why it has been studied in equine medicine). Areas of focus include:

• Soft tissue repair — promoting healing of muscle, tendon, and ligament injuries in animal models.
• Cardiac repair — cell migration and tissue regeneration in heart injury studies.
• Wound healing — accelerated closure and reduced scarring in animal wound models.
• Flexibility and range of motion — frequently reported in community use, though formal human research on this is limited.
• Anti-inflammatory effects — reduction of inflammatory markers in tissue injury models.
• Blood vessel formation — promoting angiogenesis in damaged tissue.

How it compares to BPC-157

Within the community, TB-500 is almost always discussed alongside BPC-157 — they are the two best-known "healing" research peptides, and they are sometimes stacked together in research contexts. They appear to work through different mechanisms, though, which is part of why they are often paired.

BPC-157 has been studied more in gastrointestinal and tendon-specific contexts. TB-500 is more often associated with broader soft-tissue recovery and flexibility. Reports of tolerability for both compounds are generally favorable in community discussion, with mild reactions at the injection site.

Where it fits

TB-500 occupies the recovery/repair corner of the research peptide landscape — alongside BPC-157, GHK-Cu, and a handful of others. The animal evidence for tissue-repair effects is reasonably consistent, but the human clinical data remains thin. For now, that is the honest picture.

If you want the dosing math for TB-500, the calculator handles it (a common starting reference is a 10mg vial in 2mL bacteriostatic water with twice-weekly dosing). Browse the peptide library for how it sits alongside other recovery-focused compounds.